Introduction {#Sec1}
============

Carcinogenesis is a complex, multistep process during which acquired genomic alterations may lead to chromosomal, microsatellite and epigenetic instability and thus result in cancer progression \[[@CR1]\]. Cancers are the second leading cause of morbidity and mortality worldwide \[[@CR2]\]. Colorectal cancer (CRC) is one of the most common cancers in developed regions, such as Australia, Europe and North America, and the leading cause of cancer-related deaths \[[@CR2]\]. Its incidence in these regions is high (about 55% of all cancer cases) and ranges from the second to third (depending on population ethnicity) most common type of cancer among both sexes \[[@CR2]\]. Most CRCs are sporadic, and individual susceptibility to disease is determined by: (1) environmental factors, such as occupational exposure, dietary habits and lack of physical activity, as well as (2) genetic makeup, including polymorphic variants in genes responsible for cellular metabolism and DNA repair (low-risk variants) \[[@CR3], [@CR4]\]. Despite immense progress in knowledge of genetic and environmental factors in CRC etiology, along with new treatment approaches which have been recently introduced into clinical practice, this cancer is usually diagnosed at a late stage of disease and thus 5-year overall survival is not frequent \[[@CR5]\]. Recently, macroautophagy (hereafter autophagy) has emerged as a promising independent prognostic molecular biomarker and a potential target in cancer therapy \[[@CR6]\]. Autophagy is a catabolic process enabling the maintenance of normal cell homeostasis by degrading redundant molecules and organelles ("self-eating"), but is also responsible for intracellular recycling, e.g., reuse of amino acids from degraded proteins \[[@CR7]\]. Briefly, a cargo designed for degradation is engulfed by a double-membraned vesicle, called an autophagosome, which fuses with lysosome and thus its content is decomposed by acidic enzymes \[[@CR8]\]. Autophagy is a fundamental cellular process which is highly conserved from yeasts to humans, and many yeast genes involved in autophagy have human orthologs ([A]{.ul}u[T]{.ul}opha[G]{.ul}y related; *ATG*). Autophagy, as a defense process, is usually upregulated in cells under conditions of stress, e.g., starvation \[[@CR8]\]. Thus, the energy essential for maintaining basic cellular functions may be acquired by the process of degrading proteins or organelles which are less necessary for cell survival (pivotal structures remain intact) in the process of autophagy \[[@CR8]\]. The induction of autophagy is regulated by a variety of genes, including *ULK1*, *ATG13*, *UVRAG*, *Bif*-*1* and *BECN1*. The following steps of autophagy result in the elongation and maturation of autophagosomes \[[@CR8]\]. Eventually, autophagosomes fuse with lysosomes, thus forming autophagolysosomes and their content may be degraded by hydrolases \[[@CR8]\].

Recently, autophagy has been extensively studied in different types of tumors, e.g., breast, pulmonary, prostate, brain and colorectal \[[@CR7]\]. Up to now, autophagy in carcinogenesis has been described as a double-edged sword because of its dual function. On the one hand, autophagy protects normal cells against neoplastic transformation by maintaining intracellular homeostasis, but, on the other hand, may result in cancer cells being more likely to survive than normal cells under adverse circumstances, such as hypoxia and starvation, as well as during anticancer therapy \[[@CR7], [@CR9]\]. To date, the results of many studies on autophagy in CRC are conflicting and inconclusive; thus, its function in CRC development and progression remains unclear. Recently, a complex interaction between autophagy and apoptosis was reported. However, studies have shown conflicting results \[[@CR10]\].

Because of inconclusive research data, we have focused on the mRNA expression levels of five genes involved in the induction of autophagy: *BECN1*, *UVRAG*, *ULK1*, *ATG13* and *Bif*-*1* and two genes involved in apoptosis: the antiapoptotic *BCL2* and the proapoptotic *BAX*. These expression levels were observed in both colorectal cancer cells and paired relatively normal, adjacent tissue.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Surgical samples of tissue were obtained from 73 patients with primary colorectal cancer admitted to the First Department of Surgical Oncology, Lower Silesian Oncology Center, Wroclaw, Poland, between 2010 and 2013. The mean age of the patients was 64.274 with a standard deviation of 11.066 (ranging from 35 to 88 years). The study group was evenly split with respect to sex: 49.32% female (36 of 73) and 50.68% male (37 of 73). All the tumors were classified as adenocarcinomas and were examined by two independent pathologists and classified according to the TNM classification stage criteria. Forty-six of the tumors (63%) were located on the left (descending colon, sigmoid colon and rectum) and 27 (37%) on the right (cecum and ascending colon). Patients included in the studies had no family history in regard to hereditary cancer syndromes. None of the patients received radiation or chemotherapy preoperatively. Detailed characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. Written informed consent was obtained from all patients before enrollment. The study design was accepted by the Wroclaw Medical University Ethical Committee (approval number KB-822/2012).Table 1Clinical and pathological characteristics of CRC patientsVariableTotal (%)Gender Female36 (49.3) Male37 (50.7)Age \<507 (9.6) \>5066 (90.4)Primary tumor (T) T10 T29 (12.3) T334 (46.6) T430 (41.1)Regional lymph nodes (N) Nx2 (2.7) N08 (11) N140 (54.8) N220 (27.4) N33 (4.1)Distant metastasis (M) Mx1 (1.4) M065 (89) M17 (9.6)TNM classification I3 (4.1) II6 (8.2) III57 (78.1) IV7 (9.6)Tumor location Right colon27 (37) Left colon46 (63)

Methods {#Sec4}
-------

Fresh tumor specimens and adjacent noncancerous tissue were collected in 5 ml of RNA later (Qiagen) and stored at −20 °C. Isolation of RNA was performed with the TriPure Isolation Reagent (Roche Diagnostics) following the standard protocol. The concentration, quality, purity and integrity of RNA were determined using Experion RNA StdSens Chips (Bio-Rad) for the Experion Automated Electrophoresis System (Bio-Rad). RNA samples with concentration over 100 ng/μl and RNA quality indicator (RQI) over 5 were qualified for further analysis. One microgram of total RNA from each sample was used for cDNA synthesis by reverse transcription using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics) with standard random hexamer priming according to the manufacturer's instructions. cDNA was either immediately used for PCR setup or stored at −20 °C. The expression of target genes was normalized relative to three chosen reference genes *GAPDH* (GeneID: 2597), *PPIA* (GeneID: 5478) and *RPLP0* (GeneID: 6175). A RealTime Ready Custom Panel 96-32+ (Roche Diagnostics) layout for 96 reactions in a dried-down format in 96-well plates was applied to carry out a real-time PCR assay. The custom panel assays contained target-specific primers and a matching probe from the Universal Probe Library (UPL). The RealTime Ready assays comply with the Minimum Information for Publication of Quantitative Real-time PCR Experiments (MIQE) guidelines \[[@CR11]\]. The real-time PCR mix was prepared from cDNA preparations according to the standard procedures as given by the manufacturer using the LightCycler 480 Probes Master (Roche Diagnostics) by the LightCycler 480 machine. The LightCycler 480 software, version 1.5.1, and the sample editor content \*.txt file (Roche Diagnostics) were used for sample setup, real-time PCR analysis, as well as calculation of the relative *C* ~t~ values.

Statistical analysis {#Sec5}
--------------------
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                \begin{document}$$2^{{ - {\Delta \Delta }C_{\text{t}} }}$$\end{document}$ method, as described by Livak and Schmittgen \[[@CR12]\], was applied to assess the relative difference in expression between healthy and cancer cells. Student's *t* test was used to compare means for two groups, since the group size is sufficiently large. The significance of associations was determined using Spearman's correlation coefficient, which is more robust to deviations from linear relationships and can be applied in conjunction with ordinal variables (e.g., grades). In addition to the results from these classical tests, the Benjamini--Hochberg procedure for multiple testing was applied.

Results {#Sec6}
=======

Associations with differences in expression levels between tumor cells and healthy cells {#Sec7}
----------------------------------------------------------------------------------------

The ranking of gene expression levels from the highest to the lowest values based on the delta *C* ~t~ method is as follows: in relatively healthy, adjacent normal mucosa *Bif*-*1*, *BECN1*, *ATG13*, *BAX*, *BCL2*, *ULK1*, *UVRAG*, in cancer tissue *Bif*-*1*, *BECN1*, *BAX*, *ATG13*, *BCL2*, *ULK1*, *UVRAG*, see Table [2](#Tab2){ref-type="table"}.Table 2Ranking of genes according to expressionGene*R* ~N~*Δ* ~N~95% CI*R* ~T~*Δ* ~T~95% CIBif-1 (SH3GLB1)14.20754.0660, 4.348914.59734.4431, 4.7515BECN124.65044.4952, 4.805625.16835.0235, 5.3131ATG1336.52066.3121, 6.729046.50646.3309, 6.6819BAX46.62496.3831, 6.866736.15925.9480, 6.3705BCL258.35818.0622, 8.654159.51039.1518, 9.8687ULK169.04328.6375, 9.449069.54899.2179, 9.8799UVRAG79.26748.9203, 9.6145710.11389.8233, 10.4044*Δ* ~N~ and *Δ* ~T~ denote the delta scores for normal and tumor cells, respectively. *R* ~N~ and *R* ~T~ denote the rankings according to these scores for normal and tumor cells, respectively

The mRNA relative expression levels of *BCL2*, *BECN1*, *UVRAG* and *Bif*-*1* cancer cells were lower than those in adjacent colon tissues, ranked according to the significance of the relative change in expression (*p* \< 0.05), see also Table [3](#Tab3){ref-type="table"}. The changes in the mRNA relative expression levels of *ULK1* were not significant, see Table [3](#Tab3){ref-type="table"}. The mRNA relative expression level of *BAX* was higher in cancer cells than in adjacent colon tissues (*p* \< 0.05), see Table [3](#Tab3){ref-type="table"}.Table 3Ranking of genes according to mean relative fall in expressionPos.GeneΔΔ95% CI2^−ΔΔ^95% CI1BCL2−1.1521−1.6196, −0.68472.22241.6073, 3.07292UVRAG−0.8464−1.2991, −0.39381.79801.3138, 2.46073BECN1−0.5179−0.7302, −0.30571.43191.2360, 1.65894ULK1−0.5057−1.0271, 0.01581.41980.9891, 2.03795SH3GLB1−0.3899−0.5991, −0.18061.31031.1334, 1.51486ATG130.0142−0.2594, 0.28780.99020.8191, 1.19707BAX0.46570.1446, 0.78680.72410.5796, 0.9047

Location, T, N, M, advancement {#Sec8}
------------------------------

"T" was negatively correlated with expression levels at *BAX*: (higher T correlated with higher scores, i.e., lower expression) Spearman's correlation coefficient *R* = 0.247 (*p* = 0.035). Moreover, the expression of *BAX* was lower (in comparison with adjacent, relatively normal tissue) among those patients with distant metastasis *M* = 1 (*p* = 0.047). However, these differences are not significant when the Benjamini--Hochberg procedure is applied. The expression of *BAX* was higher among tumors located on the left (*p* = 0.014), but this was not significant when the Benjamini--Hochberg procedure was taken into account.

The fall in expression levels of various genes was generally positively correlated with each other. The one exception was *BAX*. An increase in the expression level of this gene was associated with a fall in the expression level of *UVRAG*. The following correlation was significant: Spearman's correlation coefficient *R* = −0.299 (*p* = 0.010).

There were no other significant associations between the location, T, N, M staging nor degree of advancement of the tumor and the difference between the expression levels in tumor and healthy cells of any gene.

Age {#Sec9}
---

Age was positively correlated with the fall in expression levels between healthy and tumor cells of the four following genes: *BECN1* Spearman's correlation coefficient *R* = 0.343 (*p* = 0.003), *UVRAG* Spearman's correlation coefficient *R* = 0.274 (*p* = 0.019), *ATG13* Spearman's correlation coefficient *R* = 0.271 (*p* = 0.021) and *ULK1* Spearman's correlation coefficient *R* = 0.274 (*p* = 0.024). The association between age and the fall in expression of *BECN1* remains significant when the Benjamini--Hochberg procedure for multiple testing is applied.

Sex {#Sec10}
---

Sex is not significantly associated with the difference in expression levels between healthy and tumor cells of any gene.

Discussion {#Sec11}
==========

Genetic mutations leading to the activation of protooncogenes and/or loss of functioning of tumor suppressor genes may lead to the deregulation of various cellular pathways, including autophagy, and thus to cancer formation \[[@CR13]\]. Autophagy is an intracellular mechanism responsible for defense against cellular stress \[[@CR14]\]. However, its role in cancer initiation, tumor growth, anticancer therapy and treatment still remains an unanswered question \[[@CR14]\].

In our study, we have shown relative downregulation of all but one of the examined autophagy-related genes, along with antiapoptotic *BCL2*, whereas proapoptotic *BAX* was relatively upregulated. We have observed its higher expression in the early stages of CRC in comparison with normal tissue. However, *BAX* expression successively decreases as a cancer progresses and is the lowest in patients with distant metastasis. Our results are in agreement with the observations published by Jansson and Sun \[[@CR15]\]. They examined the protein expression level of BAX in normal colorectal mucosa, as well as in primary colorectal adenocarcinomas from early to advanced stages, including cases with metastases to regional lymph nodes. They reported more intense expression in primary tumors in comparison with normal tissue, but in metastatic CRC samples, lower expression levels have been observed \[[@CR15]\]. Similar results have been obtained by Cobanoglu et al., who examined expression levels of BAX and AIF (apoptosis-inducing factor). BAX staining levels were markedly higher in adenomas and carcinomas than in normal mucosa. Moreover, the BAX level was higher in carcinomas than in adenomas \[[@CR16]\].

Therefore, we may conclude that during the early stages of CRC carcinogenesis apoptosis is more prone to occur than autophagy, while during tumor progression an accumulation of genetic alterations may disturb the process of apoptosis and thus contribute to tumor progression and promotion.

We have observed a statistically significant correlation between a high expression of *BAX* and a decrease in expression of *UVRAG.* UVRAG is a well-known protein involved in autophagy initiation, through interaction with BECN1, as well as in the maturation of autophagosomes \[[@CR8]\]. Recently, UVRAG has been reported as a crucial factor in apoptosis. Yin et al. \[[@CR17]\] found that UVRAG possesses both autophagic and antiapoptotic properties mediated by its direct interaction with BAX in the cytosol, as confirmed by coimmunoprecipitation studies. These researchers have formulated the hypothesis that UVRAG exerts its cytoprotective function by controlling the localization of the BAX protein through interaction with this protein and inhibits translocation of BAX to the mitochondria and therefore prevents apoptosis \[[@CR17]\]. Increased expression of UVRAG has been observed in cells exposed to stress, such as chemotherapy and/or UV radiation. The influence of the underexpression of UVRAG on anticancer therapy has been studied in experiments in which UVRAG expression has been inhibited by specific short hairpin RNAs (sshRNAs) transfection \[[@CR17]\]. A decreased index of autophagy and increased level of apoptosis were detected \[[@CR17]\]. Therefore, the authors suggested that decreased UVRAG activity directly influences BAX-induced apoptosis in cancer cells. The authors also showed that the antiapoptotic activity of UVRAG does not affect BAX expression \[[@CR17]\]. However, UVRAG does not influence apoptosis induced by other proapoptotic proteins, such as Bad or Bid. Moreover, its direct role in the regulation of apoptosis seems to be an independent event, besides its proautophagic function \[[@CR17]\]. Thus, it was assumed that in tumor cells UVRAG plays a central role in the modulation of apoptosis in response to stressful conditions (UVRAG-BAX complex) as a negative regulator and autophagy (UVRAG-BECN1 complex) as a positive regulator \[[@CR17]\]. In our study, an elevated level of mRNA in *BAX* was shown to be associated with downregulation of the mRNA levels of *UVRAG.* Hence, we hypothesized that the promotion of apoptosis may influence the expression of *UVRAG* and therefore counteracts the induction of autophagy in CRC cells. Consequently, we conclude that high *BAX* expression may be a negative regulator of *UVRAG* gene expression.

Among the analyzed genes, we found that *Bif*-*1* (BAX-interacting factor 1) expression was the highest, both in normal and in cancer tissues. Bif-1 is also known as SH3GLB1 (SH3 domain GBR2-like endophilin B1) and belongs to the endophilin protein family \[[@CR18]\]. Bif-1 was identified as a BAX-binding protein and a necessary factor in the promotion of apoptosis \[[@CR19]\]. It has been proven that the loss of Bif-1 inhibits the following: (1) BAX/Bak conformational activation, (2) release of cytochrome c and (3) caspase activation in response to intrinsic signals of death \[[@CR19]\]. Overexpression of Bif-1 stimulates BAX and thus stimulates apoptosis. It has been hypothesized that Bif-1 may be a new type of BAX activator controlling apoptosis in the mitochondrial pathway \[[@CR20]\]. Moreover, Bif-1 is also involved in autophagy and its complex with BECN1 in conjunction with UVRAG is required for the induction of autophagosome formation \[[@CR19]\]. Coppola et al. \[[@CR20]\] found decreased levels of both Bif-1 mRNA and protein in CRC tissues. These results are in agreement with our results. The *Bif*-*1* gene is located on the short arm of chromosome 1 (locus: 1p22). This region is frequently deleted in many human cancers, including CRC \[[@CR21]--[@CR24]\]. Therefore, it has been proposed that *Bif*-*1* is a tumor suppressor gene. Loss of Bif-1 functioning may suppress apoptosis, as well as autophagy \[[@CR20]\].

The fact that the *Bif*-*1* gene had the highest level of expression among all the genes tested in our study may be explained by the fact that this protein is involved in two independent intracellular pathways connected with cell death, namely apoptosis and autophagy. We found decreased *Bif*-*1* mRNA levels in CRC samples, and therefore, we hypothesize that this decrease may result in the suppression of autophagy. However, as we also observed increased *BAX* gene expression in CRC samples, it can be argued that upregulation of apoptosis in CRC cells may be a driving force which downregulates autophagy and *Bif*-*1* downregulation leads to its inhibition.

One of the most important proteins engaged in the initiation of autophagy is BECN1 (beclin 1) encoded by the *BECN1* gene located on the long arm of chromosome 17 (locus 17q21.31). It has been hypothesized that *BECN1* acts as tumor suppressor gene, because of its frequent deletion in a variety of tumors such as breast, ovarian and prostate \[[@CR25]--[@CR27]\]. We found its expression level to be average in both tumor and normal tissue, with the level of expression being lower in tumor samples than in healthy tissue. Interestingly, the results of other authors are conflicting, as some studies found an increased BECN1 protein level in CRC samples \[[@CR28]--[@CR30]\], while some found a decreased level \[[@CR31], [@CR32]\]. Hence, its role in CRC pathogenesis remains unclear and needs to be elucidated by further analysis. We would like to emphasize that the most common methods used for the evaluation of BECN1 expression are immunohistochemistry (IHC) and Western blot. Both methods are semiquantitative, and it is difficult to found direct relationships between protein and mRNA levels, because of complex post-transcriptional and post-translational modifications \[[@CR33]\].

Intriguingly, in our research we found that mRNA levels of *BECN1* and *UVRAG* genes are positively correlated with age, as older people exhibited higher expressions of both of them in normal tissue. Higher levels of the expression of autophagy regulators responsible for the induction of autophagy in the normal tissue of older people may be explained by the age-related failure of lysosomal hydrolases and the ineffectiveness of autolysosomes (accumulation of autophagic vacuoles), which cause autophagic activity to decline \[[@CR34]\]. Therefore, in older people's cells the accumulation of redundant molecules may stimulate higher levels of expression of genes responsible for the induction of autophagy (positive feedback).

We also observed medium expression levels of the *BCL2* gene and lower expression levels in CRC samples. The BCL2 gene negatively regulates two cell death pathways: apoptosis and autophagy \[[@CR35]\]. As we found an elevated level of *BAX* and decreased level of *BCL2*, we suggest that in the early stages of CRC tumorigenesis, apoptosis is more prone to occur than autophagy. However, in metastatic samples a decrease in the expression level of *BAX* is surprisingly not accompanied by an increase in the expression of autophagy-related genes. This phenomenon should be studied more thoroughly.

We have found a complex correlation between two pathways connected with cell death. Autophagy, along with apoptosis, is responsible for normal cell development during morphogenesis and for maintaining intracellular homeostasis, as well as cell death in mature organisms \[[@CR36]\]. The interaction between both pathways is critical for the cell life cycle. However, to date the studies published on this interaction have shown conflicting results. Some proteins, such as BECN1, UVRAG, ULK1, BCL2 and BAX, have revealed a dual role and may regulate both autophagy and apoptosis \[[@CR37], [@CR38]\]. In this research, we have found that the genes engaged in the induction of autophagy *ULK1* and *UVRAG* have the lowest expression levels in both cancer and normal tissue. Medium to high expression of mRNA was found in *BCL2*, *BECN1*, *ATG13* and *BAX*. The highest expression was found in *Bif*-*1*. Further functional analysis is needed to elucidate how these two pathways (autophagy and apoptosis) are interdependent.

Summarizing, our studies enable us to formulate the hypothesis that high mRNA expression of the proapoptotic *BAX* gene may play the role of a negative regulator of autophagy in CRC development.
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